Allergan spins off ophthalmic device businesses
This article was originally published in Clinica
Eyecare company Allergan is to spin off its ophthalmic surgical and contact lens businesses to form an independent, public company, in order to focus on the more profitable specialty pharmaceutical business. The new company, which will be called Advanced Medical Optics (AMO), plans a New York listing.
You may also be interested in...
Robust natural history data sets with well-chosen outcomes are fundamental in Aetion’s regulatory feasibility tool for real-world evidence, built through analysis of US FDA case studies and guidance.
Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.
Takeda’s TAK-721 is back, ARS Pharma will be back soon to appeal neffy complete response letter, US FDA’s Project Renewal brings Temodar labeling in current day, and more highlights from the Pink Sheet’s US FDA Performance Tracker.